| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | MNT3 |
| Uniprot No | P40549 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-630aa |
| 氨基酸序列 | SRNVTSSNKLNNHASERTAVESSAFNWIEKRQHQVRSENLMNRLSAYFLPFLSRSSHKERVLLRQLGNNEIAKSDKCRYIFEVLYKIDPDWDNAQTAKFYNVDGVDNTLASLLGERLRSYDYCFLSGQLDPTAIFANSTVNPHDLQNRMFPFLKKINEESKTVMWPIITDMTTGEAVPAPEVDMESSNFNGNFWSNWNRLSKGRGFVLTIAEKDVPLFLKQLKVMEFSKNELPFQIVSTGNELSAESIAKISETAKETEQRVYLVDCSTVLDTNFANTYISFFQNKWVATLFNTFEEYILLDADVVPFVGSDYFFDSPSYRESGILLFKDRVMENEQTFQYCIEMLNEVEPSAQERRFIGSRLVFDSSLPFSSETSEEASVYYNFFKKLRLHHVDSGLVVVNKLEKLNGLLMSFMLNLDGKLQRCVYGDKEIFWLGQLYAGQDYSINPVDGSIIGPVNEEPENDDGHKSGMYYICSTQIAHSDSKNRLLWVNGGLKTCKISNSAEDDFGREPEYFKSRYGDISKLKRIYDASLNVEGLIVPDVSVHPWMQIKECSNYMYCAYATGDGHTNSELDEGRLITFTEKELRYINDISRTWNAN |
| 预测分子量 | 74.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MNT3重组蛋白的3篇示例参考文献，格式包含文献名称、作者及摘要内容概括。注：由于MNT3相关研究较为特定，以下内容为示例性描述，实际文献需通过学术数据库核实。
---
1. **文献名称**: *"Recombinant expression and functional characterization of MNT3/ST6GalNAc-III in cancer cell adhesion"*
**作者**: Yamamoto, T. et al.
**摘要**: 本研究利用大肠杆菌系统成功表达了重组MNT3(唾液酸转移酶ST6GalNAc-III)，并验证其在体外催化唾液酸转移至糖蛋白的能力。实验表明，MNT3重组蛋白通过调控细胞表面糖基化，显著增强癌细胞的迁移和粘附，提示其在肿瘤转移中的潜在作用。
2. **文献名称**: *"Structural insights into MNT3-mediated sialylation: X-ray crystallography of the recombinant enzyme"*
**作者**: Zhang, L. et al.
**摘要**: 通过重组表达并纯化人源MNT3蛋白，结合X射线晶体学解析了其三维结构。研究揭示了MNT3的活性位点及底物结合机制，为开发靶向糖基化过程的抑制剂提供了结构基础。
3. **文献名称**: *"MNT3 recombinant protein as a therapeutic target in autoimmune disorders"*
**作者**: Müller, R. et al.
**摘要**: 研究利用哺乳动物细胞(CHO)系统生产功能性MNT3重组蛋白，发现其通过调节T细胞表面糖基化抑制过度免疫反应。动物实验表明，MNT3蛋白可缓解类风湿性关节炎模型小鼠的炎症症状。
---
**提示**：若需真实文献，建议在PubMed或Web of Science中以关键词“MNT3 recombinant protein”“ST6GalNAc-III expression”检索，或结合具体研究领域(如糖生物学、癌症)进一步筛选。部分研究可能以“ST6GALNAC3”(MNT3的基因符号)为名称。
MNT3 recombinant protein, also known as SIRPα-Fc or CD172a, is a engineered fusion protein designed to modulate immune responses, particularly in the context of cancer immunotherapy. It combines the extracellular domain of Signal Regulatory Protein Alpha (SIRPα) with the Fc region of human immunoglobulin (IgG1). SIRPα is a transmembrane receptor expressed on myeloid cells (e.g., macrophages, dendritic cells) that interacts with CD47. a "don't eat me" signal protein overexpressed on cancer cells. This CD47-SIRPα axis normally inhibits phagocytosis of healthy cells but is exploited by tumors to evade immune surveillance.
The MNT3 recombinant protein acts as a CD47 antagonist by competitively binding to SIRPα receptors. Its Fc domain facilitates dimerization, enhancing binding avidity while enabling antibody-like pharmacokinetics and effector functions. Compared to anti-CD47 antibodies, MNT3 may offer improved safety by specifically targeting the myeloid cell compartment rather than broadly blocking CD47 on all nucleated cells, potentially reducing hematological toxicity.
Preclinical studies demonstrate that MNT3 disrupts the CD47-SIRPα interaction, promoting macrophage-mediated phagocytosis of tumor cells and synergizing with checkpoint inhibitors. Its development represents a strategic approach to overcome tumor immune evasion mechanisms while minimizing systemic side effects. Current research focuses on optimizing its structure, evaluating combination therapies, and addressing potential resistance mechanisms in hematological malignancies and solid tumors. This recombinant protein exemplifies the growing interest in "phagocytosis checkpoint" inhibitors as next-generation immunotherapeutics.
×
